Monthly Archives: February 2005

European Medicines Agency announces regulatory action on COX-2 inhibitors

Posted on February 18, 2005 by admin

EMEA have announced their regulatory action on COX-2 inhibitors: The following urgent safety restrictions have been taken for COX-2 inhibitors available in the European Union: A contra-indication is introduced for all COX-2 inhibitors in patients with ischaemic heart disease or … Continue reading →

Posted in EMEA | Comments Off

ADR Study Day

Posted on February 16, 2005 by admin

Don’t forget our ADR study day in April 2005! Applications from all health professionals are still welcomed. Pharmacists who wish to attend should note that the study day is now accredited by The College of Pharmacy Practice. UPDATE: [Link removed … Continue reading →

Posted in Events | Comments Off

Ezetrol (ezetimibe) – Canadian advisory

Posted on February 7, 2005 by admin

The Canadian Therapeutic Products Directorate have posted about the association of Ezetrol (ezetimibe) with myalgia, rhabdomyolysis, hepatitis, pancreatitis, and thrombocytopenia. Merck Frosst/Schering Pharmaceuticals briefing for patients. Merck Frosst/Schering Pharmaceuticals briefing for professionals.

Posted in ADRs, Health Canada | Comments Off

Co-proxamol to be withdrawn

Posted on February 1, 2005 by admin

The MHRA have advised that co-proxamol will be withdrawn from the market over the next 6-12 months because it now has an adverse risk:benefit ratio Dear Healthcare professional letter Question and Answer document

Posted in MHRA | Comments Off

New ADRAC bulletin

Posted on February 1, 2005 by admin

The Australian Adverse Drug Reaction Advisory Committee have just published their latest bulletin featuring ADRs to complementary medicines, avoiding isotretinoin in pregnancy, bisphosphonates and osteonecrosis of the jaw, and statins now contraindicated in pregnancy. html version pdf version

Posted in ADRAC | Comments Off